BSE Live
Dec 27, 11:22Prev. Close
2.05
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Balance Sheet of Pan Drugs (in Rs. Cr.) | Mar 15 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | |||||
| SHAREHOLDER'S FUNDS | |||||
| Equity Share Capital | 0.00 | 3.14 | 3.14 | 3.14 | |
| Total Share Capital | 0.00 | 3.14 | 3.14 | 3.14 | |
| Reserves and Surplus | 0.00 | -11.60 | -11.32 | -10.38 | |
| Total Reserves and Surplus | 0.00 | -11.60 | -11.32 | -10.38 | |
| Total Shareholders Funds | 0.00 | -8.45 | -8.18 | -7.24 | |
| NON-CURRENT LIABILITIES | |||||
| Long Term Borrowings | 0.00 | 0.13 | 0.07 | 0.20 | |
| Deferred Tax Liabilities [Net] | 0.00 | 1.22 | 1.22 | 1.22 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 0.00 | 1.35 | 1.29 | 1.43 | |
| CURRENT LIABILITIES | |||||
| Short Term Borrowings | 0.00 | 19.52 | 19.35 | 18.27 | |
| Trade Payables | 0.00 | 6.53 | 4.48 | 5.41 | |
| Other Current Liabilities | 0.00 | 0.28 | 2.85 | 2.79 | |
| Short Term Provisions | 0.00 | 0.14 | 0.18 | 0.15 | |
| Total Current Liabilities | 0.00 | 26.47 | 26.85 | 26.62 | |
| Total Capital And Liabilities | 0.00 | 19.37 | 19.96 | 20.81 | |
| ASSETS | |||||
| NON-CURRENT ASSETS | |||||
| Tangible Assets | 0.00 | 6.43 | 5.10 | 4.62 | |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Work-In-Progress | 0.00 | 0.00 | 1.14 | 0.15 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 0.00 | 6.43 | 6.24 | 4.77 | |
| Non-Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 0.00 | 2.48 | 2.48 | 2.48 | |
| Other Non-Current Assets | 0.00 | 0.04 | 0.04 | 0.04 | |
| Total Non-Current Assets | 0.00 | 8.95 | 8.77 | 7.29 | |
| CURRENT ASSETS | |||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 0.00 | 2.17 | 2.23 | 4.44 | |
| Trade Receivables | 0.00 | 3.91 | 4.79 | 5.80 | |
| Cash And Cash Equivalents | 0.00 | 1.97 | 1.99 | 1.18 | |
| Short Term Loans And Advances | 0.00 | 2.37 | 2.19 | 2.10 | |
| OtherCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Current Assets | 0.00 | 10.42 | 11.19 | 13.52 | |
| Total Assets | 0.00 | 19.37 | 19.96 | 20.81 | |
| OTHER ADDITIONAL INFORMATION | |||||
| CONTINGENT LIABILITIES, COMMITMENTS | |||||
| Contingent Liabilities | 0.00 | 0.00 | 1.06 | 1.06 | |
| CIF VALUE OF IMPORTS | |||||
| Raw Materials | 0.00 | 0.58 | 5.19 | 13.91 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | |||||
| Expenditure In Foreign Currency | 0.00 | 0.00 | 0.00 | 0.00 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | |||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | |||||
| FOB Value Of Goods | -- | -- | -- | -- | |
| Other Earnings | -- | 7.27 | -- | -- | |
| BONUS DETAILS | |||||
| Bonus Equity Share Capital | -- | -- | -- | -- | |
| NON-CURRENT INVESTMENTS | |||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | -- | -- | -- | -- | |
| CURRENT INVESTMENTS | |||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- |
02.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
02.04.2026
02.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth